Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

472.80 +1.68 (+0.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
53 54 Next >
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising. 
Via InvestorPlace
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Editas Medicine Stock Soared as Much as 42% Higher This Week
The clinical-stage genome editing company dropped a couple of important announcements for shareholders. 
Via The Motley Fool
3 Magnificent Growth Stocks to Buy in March
These three stocks have two important common denominators: the same industry and tremendous growth prospects. 
Via The Motley Fool
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
Goldman Sachs is removing Apple from its Conviction List of buy-rated stocks. Looking at the potential reasons why and who replaced the tech giant. 
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,500 Today
Via Benzinga
What Analysts Are Saying About Vertex Pharmaceuticals Stock
Via Benzinga
These 4 Stocks Are the "Magnificent Seven" of Healthcare
Their growth trajectories aren't as meteoric, but they're still notable. 
Via The Motley Fool
Could These 3 Companies Headline a "Magnificent Seven" of Biotech Stocks?
These stocks meet many of the criteria long-term investors look for. 
Via The Motley Fool
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
3 Biotech Stocks Bound to Blast Off By 2029
Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years. 
Via InvestorPlace
bluebird bio: How to play LEAPS options for growth and income
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT 
Via MarketBeat
Exposures Product Safety
Vertex Pharmaceuticals (VRTX) Should Remain Supported
Vertex Pharmaceuticals Incorporated (VRTX​​​​​​​), is a biotechnology company. It engages in developing & commercializing therapies for treating cystic fibrosis (CF). 
Via Talk Markets
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex shares have climbed almost 50% over the past year. 
Via The Motley Fool
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices
Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on rare diseases, escalating costs, and the impact on FDA-approved drugs. 
Via Benzinga
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
The Ultimate Growth Stock to Buy With $1,000 Right Now
The positives are many and the negatives are few with this high-flying stock. 
Via The Motley Fool
2 Stocks That Could Crush the Market in 2024
These companies aren't slowing down, and their addressable markets are widening. 
Via The Motley Fool
Three S&P 500 Giants Lead This List Of Stocks Near Buy Points
Watch these five stocks, but the market is slightly extended. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
The Best Stocks to Invest $5,000 in Right Now
These stocks could be huge winners for long-term investors. 
Via The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
3 Secret Stocks to Double Your Money by 2028
Vertex Pharmaceuticals (VRTX), UiPath (PATH), and Science Applications International (SAIC) are 3 secret stocks to double your money by 2028. 
Via InvestorPlace
Vertex to Participate in Upcoming Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar Market
Vertex's main business may be heading for a new era of growth... 
Via The Motley Fool
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
These exciting players could deliver explosive growth over time. 
Via The Motley Fool
3 Revolutionary Biotech Stocks Poised for 10X Surge
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities. 
Via InvestorPlace
3 Magnificent Growth Stocks to Buy Right Now
These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects. 
Via The Motley Fool
Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market?
The pain market is in great need of new options. 
Via The Motley Fool
2 Top Growth Stocks to Buy With $1,000 Right Now
Even a modest starting investment in the right stocks could pay off in the years ahead. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
53 54 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.